Emergent BioSolutions Inc. EBS
NYSE
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -32.70M | -180.20M | 6.80M | -54.60M | 51.20M |
| Total Depreciation and Amortization | 17.00M | 24.00M | 23.50M | 26.00M | 23.40M |
| Total Amortization of Deferred Charges | 1.60M | 1.60M | 1.80M | 2.60M | 2.50M |
| Total Other Non-Cash Items | -18.10M | 235.40M | -14.10M | 21.70M | 2.00M |
| Change in Net Operating Assets | 132.30M | -24.70M | -51.80M | 82.00M | -81.40M |
| Cash from Operations | 100.10M | 56.10M | -33.80M | 77.70M | -2.30M |
| Capital Expenditure | -3.30M | -2.10M | -2.40M | -3.90M | -3.40M |
| Sale of Property, Plant, and Equipment | 5.40M | 200.00K | -- | 0.00 | 0.00 |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 2.50M | -50.40M | -- | 0.00 | 0.00 |
| Cash from Investing | 4.60M | -52.30M | -2.40M | -3.90M | -3.40M |
| Total Debt Issued | 0.00 | 145.50M | -- | -- | -- |
| Total Debt Repaid | -68.50M | -150.00M | -- | -105.60M | -6.90M |
| Issuance of Common Stock | 100.00K | 1.00M | 400.00K | 1.20M | 200.00K |
| Repurchase of Common Stock | -300.00K | -9.40M | -11.80M | -9.50M | -9.20M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | -11.50M | -- | -- | -- |
| Cash from Financing | -68.70M | -24.40M | -11.40M | -113.90M | -15.90M |
| Foreign Exchange rate Adjustments | -- | -- | -- | 0.00 | -200.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 36.00M | -20.60M | -47.60M | -40.10M | -21.80M |